Phoremost Ltd

PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes

Investment to enable progression of pipeline of novel degrader assets through pre-clinical development and support further development of GlueSEEKER platform Led by Parkwalk Advisors alongside existing investors BGF, Dr Jonathan Milner, Amadeus Capital and Astellas Venture Management 10 September 2024 -- Cambridge, UK -- PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation...

PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders

New drug discovery platform integrates computational approaches with molecular biology for development of novel degrader therapeutics 21 May 2024 -- Cambridge, UK -- PhoreMost, a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKER. The new phenotypic screening platform expands the company’s capabilities in this emerging therapeutic...

PhoreMost Enters Multi-Project Drug Target Discovery Collaboration With Roche

Cambridge, UK, 06 September 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ëDrugging the Undruggableí disease targets, today announced it has entered into a multi-project target discovery collaboration with Roche, one of the world's leading biotechnology companies. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical...

PhoreMost Promotes Dr Neil Torbett to Chief Executive Officer

Cambridge, UK, 01 March 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ëDrugging the Undruggableí disease targets, today announced the promotion of Dr Neil Torbett to Chief Executive Officer, with immediate effect. Dr Torbett was previously the Companyís Chief Operating Officer. Founder and former CEO, Dr Chris Torrance will become Chair of the Board.

PhoreMost expands into new facility at Unity Campus, Cambridge, UK

Cambridge, UK, 18 January 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ëDrugging the Undruggableí disease targets, today announced it has relocated its headquarters to Unity Campus, a high-specification technology and innovation park, owned by leading regional property developers and investors, Howard Group, in south Cambridge.

PhoreMost Ltd and University of Cambridge collaborate to identiovative drug targets for neurodegenerative disease

Cambridge, UK, 12 October 2016: PhoreMost Ltd (PhoreMost), a biopharmaceutical company dedicated to drugging ëundruggableí disease targets, has entered into a research collaboration with the laboratory of Professor David Rubinsztein at the University of Cambridge. The groups will study and translate essential cellular mechanisms of neurodegenerative disorders into novel therapeutic strategies for diseases such as...
PhoreMost Ltd, Building B580, Room 2011, Babraham Research Campus, Babraham, Cambridge, CB22 3AT, United Kingdom

+44 (0)1223 804 163